|
1
|
Li XL, Liu XX, Cao GS, Ju DD and Jiang H:
Narrowing resection of parametrial tissues is feasible in low-risk
cases of stage IA2-IB1 cervical cancer. J Cancer. 7:1481–1486.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tjalma WAA: Diagnostic performance of
dual-staining cytology for cervical cancer screening: A systematic
literature review. Eur J Obstet Gynecol Reprod Biol. 210:275–280.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen J, Stass SA and Jiang F: MicroRNAs as
potential biomarkers in human solid tumors. Cancer Lett.
329:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gonzalez-Quintana V, Palma-Berre L,
Campos-Parra AD, López-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo
R and Pérez-Plasencia C: MicroRNAs are involved in cervical cancer
development, progression, clinical outcome and improvement
treatment response (Review). Oncol Rep. 35:3–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava SK, Ahmad A, Zubair H, Miree O,
Singh S, Rocconi RP, Scalici J and Singh AP: MicroRNAs in
gynecological cancers: Small molecules with big implications.
Cancer Lett. 407:123–138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shahjahani M, Khodadi E, Seghatoleslami M,
Asl JM, Golchin N, Zaieri ZD and Saki N: Rare cytogenetic
abnormalities and alteration of microRNAs in acute myeloid leukemia
and response to therapy. Oncol Rev. 9:2612015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao L, Guo Q, Li X, Yang X, Ni H, Wang T,
Zhao Q, Liu H, Xing Y, Xi T and Zheng L: MiR-873/PD-L1 axis
regulates the stemness of breast cancer cells. EBioMedicine.
41:395–407. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li G, Xu Y, Wang S, Yan W, Zhao Q and Guo
J: MiR-873-5p inhibits cell migration, invasion and
epithelial-mesenchymal transition in colorectal cancer via
targeting ZEB1. Pathol Res Pract. 215:34–39. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin S, He J, Li J, Guo R, Shu Y and Liu P:
MiR-873 inhibition enhances gefitinib resistance in non-small cell
lung cancer cells by targeting glioma-associated oncogene homolog
1. Thorac Cancer. 9:1262–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang Y, Zhang P, Li S, Li H, Song S and
Lu B: MicroRNA-873 acts as a tumor suppressor in esophageal cancer
by inhibiting differentiated embryonic chondrocyte expressed gene
2. Biomed Pharmacother. 105:582–589. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo J, Zhu H, Jiang H, Cui Y, Wang M, Ni X
and Ma C: The effects of aberrant expression of LncRNA
DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression. Cancer Med.
May 23–2018.doi: 10.1002/cam4.1566 (Epub ahead of print).
View Article : Google Scholar
|
|
14
|
Cao D, Yu T and Ou X: MiR-873-5P controls
gastric cancer progression by targeting hedgehog-GLI signaling.
Pharmazie. 71:603–606. 2016.PubMed/NCBI
|
|
15
|
Gao Y, Xue Q, Wang D, Du M, Zhang Y and
Gao S: miR-873 induces lung adenocarcinoma cell proliferation and
migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526.
2015.PubMed/NCBI
|
|
16
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang
Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα
transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 34:3895–3907. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han
S, Peng B, Liu W and He X: MiR-873 acts as a novel sensitizer of
glioma cells to cisplatin by targeting Bcl-2. Int J Oncol.
47:1603–1611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qureshi R, Arora H and Rizvi MA: EMT in
cervical cancer: Its role in tumour progression and response to
therapy. Cancer Lett. 356:321–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang JS, Zhao Y, Lv Y, Liu PY, Ruan JX,
Sun YL, Gong TX, Wan N and Qiu GR: miR-873 suppresses H9C2
cardiomyocyte proliferation by targeting GLI1. Gene. 626:426–432.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabol M, Trnski D, Musani V, Ozretic P and
Levanat S: Role of GLI transcription factors in pathogenesis and
their potential as new therapeutic targets. Int J Mol Sci. 19(pii):
E25622018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Didiasova M, Schaefer L and Wygrecka M:
Targeting GLI transcription factors in cancer. Molecules. 23(pii):
E10032018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Skoda AM, Simovic D, Karin V, Kardum V,
Vranic S and Serman L: The role of the Hedgehog signaling pathway
in cancer: A comprehensive review. Bosn J Basic Med Sci. 18:8–20.
2018. View Article : Google Scholar : PubMed/NCBI
|
